Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021 02; 9(2).
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antibodies, Bispecific
Antineoplastic Agents, Immunological
CD40 Antigens
Female
France
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms
Time Factors
Tumor Microenvironment
United States
authors with profiles
Hedy Kindler